Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RapMed-1506
- Development stage
- Unknown
- Lead developer
- RAPHAS
- Modality
- Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Percutaneous
01
Overview
RapMed-1506 (also known as DF19001) is an allergen-specific immunotherapy (AIT) developed by RAPHAS for the treatment of allergic rhinitis caused by house dust mite (HDM) allergens. The product utilizes a dissolving microneedle patch delivery system, which is designed to deliver HDM allergens into the skin to induce immunological tolerance. This modality aims to improve patient compliance and safety compared to traditional subcutaneous injections or sublingual immunotherapy. A Phase 1 clinical trial (NCT05525650) was conducted in South Korea to evaluate the safety and tolerability of the patch in subjects with HDM-induced allergic rhinitis, with the study completing in early 2025.
- Other names
- DF19001DF-19001DF 19001
02
Targets
TCR (T cell antigen receptor complex)House dust mite-specific B-cell receptorHDM-specific IgE (House dust mite-specific immunoglobulin E)
Beyond the preview
Go deeper on RapMed-1506.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RapMed-1506.